Press Room

Webinar - One - fruitful - long shot: extended release approaches for small and large molecules

Start
Wednesday, November 25, 2020 - 16:00
End
Wednesday, November 25, 2020 - 16:00
Location: online

 

Wednesday, November 25th, 2020
4:00pm GMT   |   11:00 am EDT  |   5:00 pm CEST

 

Registrations to the webinar are subject to approval

 

 

Speakers

Cláudia Moura, PhD - Senior Scientist, R&D Drug Product Development
Teresa Marta, MSc - Associate Analytical Chemist, R&D Analytical Development

 

Drug-delivery systems administered by injection that allows controlled-release are highly desirable due to the reduced frequency of administrations that can range from weeks to months or even years, increasing patient compliance while providing the same therapeutic efficiency.

In this webinar, we will address insights into the formulation and available particle engineering technologies for controlled delivery of small molecules and biopharmaceuticals using Poly(lactic-co-glycolic) Acid (PLGA) as biodegradable polymer. We will also explore standard and advanced material characterization techniques including accelerated in vitro release (IVR) methods which have received considerable attention to expedite time required for batch release. 

This webinar will present Hovione’s approach for controlled release PLGA formulations throughout the manufacturing process and product characterization. You can hear about several manufacturing techniques available at Hovione that are followed by case-studies; the analytical characterization will also be showcased focusing on real time and accelerated IVR.

 

What can you learn from this webinar?

  • Controlled release systems - delivery routes
  • Formulation and manufacturing approaches

 

 

Watch On-Demand Webinar!

(Restricted Access)

 

 

 

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024